TY - JOUR
T1 - Big picture initiatives in bleeding disorders
AU - Rauch, Antoine
AU - Valentino, Leonard A.
AU - Mills, Kevin
AU - Witkop, Michelle L.
AU - Santaella, Maria E.
AU - DiMichele, Donna
AU - Recht, Michael
AU - Susen, Sophie
N1 - Funding Information:
The authors wish to acknowledge Karina Lopez for her assistance in preparing the manuscript along with the all the participants who shared their time and insights during the process.
Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2022/5
Y1 - 2022/5
N2 - Introduction: The inherited bleeding disorders (IBD) community has witnessed significant therapeutic advances recently, yet important gaps persist, particularly for those with rare disorders and historically underserved populations. Aims: -To create a national research blueprint agenda, led by the National Hemophilia Foundation (NHF), enhancing patient-centric principles, accelerate research progress and address important gaps in care. -To review critical gaps that remain to be addressed in women with IBDs, who face specific bleeding challenges. Methods: The NHF research blueprint research agenda was defined by input from across the community, including caregivers and patients who are considered subject matter experts of their IBD, research leaders, allied health professionals and specialists, and representatives of the biopharmaceutical industry. In addition, two medical experts in the field of IBDs performed a comprehensive review to address the knowledge gaps in women with IBDs. Results: Two foundational principles of the NHF blueprint are: (1) it must deliver on key issues that significantly impact the lives of those affected by IBDs, and (2) the priorities defined are relevant and actionable aimed to achieve health equity among all those affected by IBDs. A multidisciplinary approach is necessary for an optimal management of puberty, transition to adulthood and pregnancy. Even if strict guidelines are followed, recent studies show that women with IBDs are still facing a high burden. Conclusion: NHF blueprint will be issued in 2022. A specific research agenda is needed in women with IBDs to further improve their management and quality of life.
AB - Introduction: The inherited bleeding disorders (IBD) community has witnessed significant therapeutic advances recently, yet important gaps persist, particularly for those with rare disorders and historically underserved populations. Aims: -To create a national research blueprint agenda, led by the National Hemophilia Foundation (NHF), enhancing patient-centric principles, accelerate research progress and address important gaps in care. -To review critical gaps that remain to be addressed in women with IBDs, who face specific bleeding challenges. Methods: The NHF research blueprint research agenda was defined by input from across the community, including caregivers and patients who are considered subject matter experts of their IBD, research leaders, allied health professionals and specialists, and representatives of the biopharmaceutical industry. In addition, two medical experts in the field of IBDs performed a comprehensive review to address the knowledge gaps in women with IBDs. Results: Two foundational principles of the NHF blueprint are: (1) it must deliver on key issues that significantly impact the lives of those affected by IBDs, and (2) the priorities defined are relevant and actionable aimed to achieve health equity among all those affected by IBDs. A multidisciplinary approach is necessary for an optimal management of puberty, transition to adulthood and pregnancy. Even if strict guidelines are followed, recent studies show that women with IBDs are still facing a high burden. Conclusion: NHF blueprint will be issued in 2022. A specific research agenda is needed in women with IBDs to further improve their management and quality of life.
KW - heavy menstrual bleeding
KW - inherited bleeding disorders
KW - postpartum haemorrhage
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85129419683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129419683&partnerID=8YFLogxK
U2 - 10.1111/hae.14532
DO - 10.1111/hae.14532
M3 - Article
C2 - 35521733
AN - SCOPUS:85129419683
SN - 1351-8216
VL - 28
SP - 53
EP - 60
JO - Haemophilia
JF - Haemophilia
IS - S4
ER -